221 related articles for article (PubMed ID: 34897409)
1. Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study.
Goldman A; Raschi E; Cukierman-Yaffe T; Dankner R; Shouval R; Shechter M; Ben-Zvi I; Gerstein HC; Maor E
Eur J Prev Cardiol; 2022 Jul; 29(9):1334-1342. PubMed ID: 34897409
[TBL] [Abstract][Full Text] [Related]
2. Ocular disorders associated with PCSK9 inhibitors: A pharmacovigilance disproportionality analysis.
Zhao X; Wu J; Zhu S
Br J Clin Pharmacol; 2023 Feb; 89(2):458-469. PubMed ID: 35973681
[TBL] [Abstract][Full Text] [Related]
3. Psychiatric disorders associated with PCSK9 inhibitors: A real-world, pharmacovigilance study.
Deng Z; Liu J; Gong H; Cai X; Xiao H; Gao W
CNS Neurosci Ther; 2024 Apr; 30(4):e14522. PubMed ID: 37950531
[TBL] [Abstract][Full Text] [Related]
4. Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS.
Feng Z; Li X; Tong WK; He Q; Zhu X; Xiang X; Tang Z
Front Pharmacol; 2022; 13():894685. PubMed ID: 36506552
[No Abstract] [Full Text] [Related]
5. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database.
Wu X; Zhang L; Huang H; Huang L; Lu X; Wang Z; Xiao J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):422-434. PubMed ID: 37164926
[TBL] [Abstract][Full Text] [Related]
6. Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system.
Ji C; Bai J; Zhou J; Zou Y; Yu M
Br J Clin Pharmacol; 2022 Dec; 88(12):5317-5325. PubMed ID: 35818959
[TBL] [Abstract][Full Text] [Related]
7. Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy.
Goldman A; Maor E; Bomze D; Liu JE; Herrmann J; Fein J; Steingart RM; Mahmood SS; Schaffer WL; Perales MA; Shouval R
J Am Coll Cardiol; 2021 Nov; 78(18):1800-1813. PubMed ID: 34711339
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021.
Wang Y; Cui C; Ren X; Dong X; Cui W
Front Cardiovasc Med; 2022; 9():988013. PubMed ID: 36312283
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022.
Wang Y; Cui C; Deng L; Wang L; Ren X
Front Immunol; 2023; 14():1127128. PubMed ID: 37292205
[TBL] [Abstract][Full Text] [Related]
10. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
11. PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database.
di Mauro G; Zinzi A; Scavone C; Mascolo A; Gaio M; Sportiello L; Ferrajolo C; Rafaniello C; Rossi F; Capuano A
Drug Saf; 2021 Mar; 44(3):337-349. PubMed ID: 33351170
[TBL] [Abstract][Full Text] [Related]
12. Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System.
Ding L; Chen C; Yang Y; Fang J; Cao L; Liu Y
Cardiovasc Ther; 2022; 2022():9866486. PubMed ID: 35140810
[TBL] [Abstract][Full Text] [Related]
13. Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database.
Wei L; Tian Y; Chen X; Guo X; Chen C; Zheng Y; Xu J; Ye X
Int J Clin Pharm; 2023 Jun; 45(3):622-629. PubMed ID: 36848023
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Toxicities Associated With Ibrutinib.
Salem JE; Manouchehri A; Bretagne M; Lebrun-Vignes B; Groarke JD; Johnson DB; Yang T; Reddy NM; Funck-Brentano C; Brown JR; Roden DM; Moslehi JJ
J Am Coll Cardiol; 2019 Oct; 74(13):1667-1678. PubMed ID: 31558250
[TBL] [Abstract][Full Text] [Related]
15. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
[TBL] [Abstract][Full Text] [Related]
16. Pregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS).
Wu T; Shi Y; Zhu B; Li D; Li Z; Zhao Z; Zhang Y
Expert Opin Drug Saf; 2024 Mar; 23(3):313-321. PubMed ID: 37612600
[TBL] [Abstract][Full Text] [Related]
17. Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database.
Zhao H; Li JM; Li ZR; Zhang Q; Zhong MK; Yan MM; Qiu XY
Front Pharmacol; 2023; 14():1182113. PubMed ID: 37502210
[No Abstract] [Full Text] [Related]
18. Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database.
Wu T; Zhang Y; Shi Y; Yu K; Zhao M; Liu S; Zhao Z
Clin Drug Investig; 2022 Nov; 42(11):965-975. PubMed ID: 36175609
[TBL] [Abstract][Full Text] [Related]
19. Neurocognitive Disorders Associated with PCSK9 Inhibitors: a Pharmacovigilance Disproportionality Analysis.
Gouverneur A; Sanchez-Pena P; Veyrac G; Salem JE; Bégaud B; Bezin J
Cardiovasc Drugs Ther; 2023 Apr; 37(2):271-276. PubMed ID: 34436707
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study.
Goldman A; Bomze D; Dankner R; Fourey D; Boursi B; Arad M; Maor E
Target Oncol; 2021 Jul; 16(4):471-483. PubMed ID: 33970401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
